Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Trafficking protein particle complex subunit 1 (TRAPPC1)
- Target
- TRAPPC1
- Molecular classification
- Other (core component of multi-subunit vesicle tethering complex; not a classic receptor, enzyme, transporter, or transcription factor)
01
Overview
Trafficking protein particle complex subunit 1 (TRAPPC1) is a highly conserved core component of the transport protein particle (TRAPP) complexes, required for the vesicular transport of proteins from the endoplasmic reticulum to the Golgi apparatus[3]. TRAPPC1 ensures homeostasis of the endoplasmic reticulum and Golgi apparatus by regulating the trafficking and processing of newly synthesized proteins. It is essential for the differentiation and maintenance of common myeloid progenitors in the bone marrow, and its deficiency leads to endoplasmic reticulum stress, Golgi dysfunction, increased apoptosis, cell cycle arrest (via p21), and defective myeloid cell development. TRAPPC1 does not fit classic target categories such as receptor or enzyme and, while experimentally modulated in disease models, is not a current therapeutic target[1][2][3].
- Other names
- BET5BET5 homologMUM2MUM-2multiple myeloma protein 2melanoma ubiquitous mutated 2
02
Mechanism of action
No direct drugs targeting TRAPPC1; experimental rescue of TRAPPC1-deficient myeloid progenitors via inhibition of endoplasmic reticulum stress pathway or PERK pathway
03
Biological functions
Protein traffickingVesicle-mediated transportEndoplasmic reticulum-to-Golgi transportMaintenance of endoplasmic reticulum and Golgi homeostasisRegulation of myeloid cell differentiation and survivalRegulation of autophagy
04
Disease associations
Hematopoietic disorders (via bone marrow myeloid cell defects)Possible immune dysfunctionNot classically associated with cancer, inflammation, or neurodegeneration in current literature
05
Safety considerations
No known therapeutic targeting, so no direct safety profileknockout leads to myeloid deficiency and bone marrow dysfunction in animal models
06
Interacting drugs
TUDCA (tauroursodeoxycholic acid) and GSK2606414 (only in experimental models, for endoplasmic reticulum stress and PERK inhibition, respectively—not direct TRAPPC1 inhibitors)
07
Biomarkers
Not established as a clinical biomarkerloss or decreased expression indicates endoplasmic reticulum/Golgi dysfunction in hematopoietic cells
Beyond the preview
Go deeper on Trafficking protein particle complex subunit 1 (TRAPPC1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trafficking protein particle complex subunit 1 (TRAPPC1).